EVERY IMMUNE SYSTEM HAS A STORY TO TELL. THE KEY IS KNOWING HOW TO LISTEN.

Serial Number 90459471
Registration 7443900
700

Registration Progress

Application Filed
Jan 11, 2021
Under Examination
Nov 2, 2021
Approved for Publication
Sep 7, 2021
Published for Opposition
Sep 7, 2021
Registered
Jul 9, 2024

Trademark Image

EVERY IMMUNE SYSTEM HAS A STORY TO TELL. THE KEY IS KNOWING HOW TO LISTEN.

Basic Information

Serial Number
90459471
Registration Number
7443900
Filing Date
January 11, 2021
Registration Date
July 9, 2024
Published for Opposition
September 7, 2021
Drawing Code
4

Status Summary

Current Status
Active
Status Code
700
Status Date
Jul 9, 2024
Registration
Registered
Classes
042

Rights Holder

Adaptive Biotechnologies Corp.

03
Address
1551 Eastlake Avenue E, Suite 200
Seattle, WA 98102

Ownership History

Adaptive Biotechnologies Corp.

Original Applicant
03
Seattle, WA

Adaptive Biotechnologies Corp.

Owner at Publication
03
Seattle, WA

Adaptive Biotechnologies Corp.

Original Registrant
03
Seattle, WA

Legal Representation

Attorney
Hoang-chi Truong

USPTO Deadlines

Next Deadline
1634 days remaining
Section 8 Declaration Due (Principal Register) (Based on registration date 20240709)
Due Date
July 09, 2030
Grace Period Ends
January 09, 2031
Additional deadlines exist. Contact your attorney for complete deadline information.

Application History

35 events
Date Code Type Description Documents
Jul 9, 2024 NRCC E NOTICE OF REGISTRATION CONFIRMATION EMAILED Loading...
Jul 9, 2024 R.PR A REGISTERED-PRINCIPAL REGISTER Loading...
May 31, 2024 SUNA E NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED Loading...
May 31, 2024 CNPR P ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED Loading...
May 30, 2024 SUPC I STATEMENT OF USE PROCESSING COMPLETE Loading...
May 28, 2024 AITU A CASE ASSIGNED TO INTENT TO USE PARALEGAL Loading...
Apr 30, 2024 EISU I TEAS STATEMENT OF USE RECEIVED Loading...
Nov 4, 2023 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Nov 2, 2023 EX4G S SOU EXTENSION 4 GRANTED Loading...
Nov 2, 2023 EXT4 S SOU EXTENSION 4 FILED Loading...
Nov 2, 2023 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
May 3, 2023 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
May 1, 2023 EX3G S SOU EXTENSION 3 GRANTED Loading...
May 1, 2023 EXT3 S SOU EXTENSION 3 FILED Loading...
May 1, 2023 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Nov 4, 2022 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Nov 2, 2022 EX2G S SOU EXTENSION 2 GRANTED Loading...
Nov 2, 2022 EXT2 S SOU EXTENSION 2 FILED Loading...
Nov 2, 2022 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
May 4, 2022 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
May 2, 2022 EX1G S SOU EXTENSION 1 GRANTED Loading...
May 2, 2022 EXT1 S SOU EXTENSION 1 FILED Loading...
May 2, 2022 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Nov 2, 2021 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT Loading...
Sep 7, 2021 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Sep 7, 2021 PUBO A PUBLISHED FOR OPPOSITION Loading...
Aug 18, 2021 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Aug 2, 2021 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Jul 28, 2021 XAEC I EXAMINER'S AMENDMENT ENTERED Loading...
Jul 28, 2021 GNEN O NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED Loading...
Jul 28, 2021 GNEA F EXAMINERS AMENDMENT E-MAILED Loading...
Jul 28, 2021 CNEA R EXAMINERS AMENDMENT -WRITTEN Loading...
Jul 20, 2021 DOCK D ASSIGNED TO EXAMINER Loading...
Apr 11, 2021 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Jan 14, 2021 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 042
Providing medical diagnostic assays and diagnostic and prognostic testing for medical research purposes of residual disease, and the analysis, evaluation, and reporting of those test results to help healthcare professionals for research purposes; development of new technology for others in the field of biotechnology; DNA analysis services for scientific research purposes; genetic testing for scientific research purposes; genome amplification; genotyping services for research or analysis purposes; laboratory research in the field of immune sequencing; medical and scientific research in the field of cancer treatment and diagnosis; medical and scientific research in the field of immune sequencing; providing laboratory research services in the field of gene expression, namely, cancer biology; providing medical and scientific research information in the field of clinical trials; providing medical and scientific research information in the fields of pharmaceuticals and genetics; research and development in the pharmaceutical and biotechnology fields; research, development, engineering and testing services in the fields of immunopharmaceuticals and vaccines; scientific research in the field of genetics and genetic engineering; DNA screening for scientific research purposes; medical research; consulting services in the fields of biotechnology, pharmaceutical research and development and genetic science; consulting services in the fields of biotechnology, pharmaceutical research and development, laboratory testing, diagnostics, and pharmacogenetics; custom design and development of chemical reagents and biochemical assays; development of new technology for others in the field of immunotherapy; laboratory research in the field of immunotherapy, oncology, hematology, auto-immune disorders, and infectious diseases; medical and scientific research in the field of immunotherapy; medical laboratory services
First Use Anywhere: 20200800
First Use in Commerce: 20200800

Classification

International Classes
042